UNSPSC 51292105: Levoprotiline hydrochloride

This classification denotes an antidepressant agent with the molecular formula C20H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DFI134OU66, chemically known as 9,10-ethanoanthracene-9(10h)-ethanol, alpha-((methylamino)methyl)-, hydrochloride, (r)-, but more generally known as levoprotiline hydrochloride, which bears US NIH Compound Identifier 3033631. European Medicines Agency schedules levoprotiline hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08488MIG.

Most nations, for tariff purposes, schedule levoprotiline hydrochloride under HS 29221980. SMILES: CNC[C@@H](CC12CCC(C3C1CCCC3)C4C2CCCC4)O.CL.

UNSPSC 51292105 Levoprotiline hydrochloride is a Commodity code that does not reflect the pharmaceutical procurement activity currently being solicited by state and local governments. The recent opportunities tagged to this code show minimal alignment with levoprotiline hydrochloride specifically — a beta-adrenergic agonist used in cardiovascular therapy — and instead span broader pharmaceutical and public-health procurement including naloxone, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local issuing bodies are procuring pharmaceutical products and drug-delivery systems through diverse mechanisms: direct purchases of specific drugs and medical countermeasures, cooperative purchasing vehicles for bulk generic pharmaceuticals and OTC products distributed across multiple jurisdictions, and exploratory information-gathering on direct-to-manufacturer contracting models.

Recent opportunities reflect activity across three distinct issuing bodies and states. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, to procure naloxone and drug deactivation systems annually through competitive bidding with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and effective date of July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The code shows little recent activity directly relevant to levoprotiline hydrochloride procurement; the mismatch between the nominal code and actual recent solicitations suggests either a tagging error in the source data or that this specific pharmaceutical commodity does not currently drive state and local procurement volume.